Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to provide written informed consent.~* Diagnosis of Retinal Vein Occlusion with macular edema and central foveal thickness of greater than or equal to 300 microns confirmed by intravenous fluorescein angiography and Optical Coherence Tomography~* Visual Acuity between 20/25 and 5/200~Exclusion Criteria:~* Bilateral Retinal Vein Occlusion~* Vision worse than 5/200 in study eye~* History of myocardial infarction, ischemia, or cerebrovascular accident within 6 weeks of screening~* Concurrent Proliferative Diabetic Retinopathy and/or Maculopathy~* Concurrent Exudative Age-related Macular Degeneration~* Concurrent optic neuropathy with the presence of an afferent pupillary defect~* Previous vitrectomy in the study eye~* Currently pregnant or planning to become pregnant during the duration of the study. Women currently breastfeeding are also excluded.~* Previous treatment for retinal vein occlusion in the study eye~* Any current medical condition which, in the opinion of the investigator is considered to be uncontrolled~* History of allergy or hypersensitivity to study treatment, fluorescein, or any study procedure and treatment related ingredients (e.g. topical anesthetics, betadine, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: OTHER): All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).